196 related articles for article (PubMed ID: 22609775)
1. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation.
Zhang YY; Zhou LM
Biochem Biophys Res Commun; 2012 Jun; 423(1):26-31. PubMed ID: 22609775
[TBL] [Abstract][Full Text] [Related]
2. Sirt3 is a tumor suppressor in lung adenocarcinoma cells.
Xiao K; Jiang J; Wang W; Cao S; Zhu L; Zeng H; Ouyang R; Zhou R; Chen P
Oncol Rep; 2013 Sep; 30(3):1323-8. PubMed ID: 23842789
[TBL] [Abstract][Full Text] [Related]
3. {2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic acid methyl ester (MIAM) inhibited human hepatocellular carcinoma growth through upregulation of Sirtuin-3 (SIRT3).
Li Y; Wang W; Xu X; Sun S; Qu XJ
Biomed Pharmacother; 2015 Feb; 69():125-32. PubMed ID: 25661348
[TBL] [Abstract][Full Text] [Related]
4. Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway.
Song CL; Tang H; Ran LK; Ko BC; Zhang ZZ; Chen X; Ren JH; Tao NN; Li WY; Huang AL; Chen J
Oncogene; 2016 Feb; 35(5):631-41. PubMed ID: 25915842
[TBL] [Abstract][Full Text] [Related]
5. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Tao NN; Zhou HZ; Tang H; Cai XF; Zhang WL; Ren JH; Zhou L; Chen X; Chen K; Li WY; Liu B; Yang QX; Cheng ST; Huang LX; Huang AL; Chen J
Oncotarget; 2016 Aug; 7(31):50117-50130. PubMed ID: 27367026
[TBL] [Abstract][Full Text] [Related]
6. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
[TBL] [Abstract][Full Text] [Related]
7. SIRT3 functions as a tumor suppressor in hepatocellular carcinoma.
Zeng X; Wang N; Zhai H; Wang R; Wu J; Pu W
Tumour Biol; 2017 Mar; 39(3):1010428317691178. PubMed ID: 28347248
[TBL] [Abstract][Full Text] [Related]
8. Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal‑regulated kinase signaling pathway.
Zhang ZG; Qin CY
Mol Med Rep; 2014 Mar; 9(3):882-8. PubMed ID: 24366394
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
10. [Role of SIRT3 in regulating proliferation of hepatocellular carcinoma cells in vitro].
Tao Y; Chen J
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Feb; 36(2):195-9. PubMed ID: 26922015
[TBL] [Abstract][Full Text] [Related]
11. NCPMF-60 induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells.
Dai QS; Liu W; Wang XB; Lu N; Gong DD; Kong LY; Guo QL
Anticancer Drugs; 2011 Jan; 22(1):46-57. PubMed ID: 20948430
[TBL] [Abstract][Full Text] [Related]
12. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
13. [ShRNA-mediated silencing of MDM2 inhibits growth of HepG2 hepatocellular carcinoma cells xenografted in nude mice].
Zhao YY; Li YG; Sun YJ; Liu HP; Yang ZC; Zhang DD; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):213-7. PubMed ID: 23967744
[TBL] [Abstract][Full Text] [Related]
14. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
[TBL] [Abstract][Full Text] [Related]
15. MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development.
Xie X; Wang X; Liao W; Fei R; Wu N; Cong X; Chen Q; Wei L; Wang Y; Chen H
J Exp Clin Cancer Res; 2018 Feb; 37(1):28. PubMed ID: 29439719
[TBL] [Abstract][Full Text] [Related]
16. The expression of SIRT3 in primary hepatocellular carcinoma and the mechanism of its tumor suppressing effects.
Liu Y; Liu YL; Cheng W; Yin XM; Jiang B
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(5):978-998. PubMed ID: 28338198
[TBL] [Abstract][Full Text] [Related]
17. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
18. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells.
Zhang YY; Zhou LM
Eur J Pharmacol; 2013 Jan; 698(1-3):137-44. PubMed ID: 23178529
[TBL] [Abstract][Full Text] [Related]
19. MCU-dependent mitochondrial Ca
Ren T; Zhang H; Wang J; Zhu J; Jin M; Wu Y; Guo X; Ji L; Huang Q; Zhang H; Yang H; Xing J
Oncogene; 2017 Oct; 36(42):5897-5909. PubMed ID: 28650465
[TBL] [Abstract][Full Text] [Related]
20. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
